WOCKPHARMA Wockhardt Q4 FY25 results (Jan–Mar 2025) and concall
Wockhardt has successfully transitioned from a generic-focused firm to a research-driven organization, with its NCE (New Chemical Entity) portfolio nearing commercialization. The company significantly strengthened its balance sheet through a ₹1,000 crore QIP, bringing net debt down to near-zero levels. Management is now focused on the global launch of ZAYNICH and expanding its biosimilar capacity to capitalize on market gaps left by competitors like Novo Nordisk.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 809 | 721 | 743 |
| EBITDA | 110 | 128 | 64 |
| Net profit | -16 | 20 | -45 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
